As of today, 31 Senators (31% of total Senators) and 157 House members (36% of total) have cosponsored the 2015 Medicare CGM Access Act, solid progress since the bill was reintroduced in March. However, over 50% of Congressional and Senate Diabetes Caucus members have yet to co-sponsor the bill.
A study published in the journal Diabetes Care found that inhaled formoterol has the potential to help treat hypoglycemia in people with Type 1 diabetes.
A new study finds that people with diabetes in the U.S. are paying between 5.7 times and 7.5 times more than those in the UK for two popular insulins and a rare drug to treat diabetic retinopathy. U.S. consumers absorb this higher cost despite often not being the first in line to have access to […]
Mike tells a story about how your smartphone and CGM can save you from dangerous hypoglycemia.
The study measures customer satisfaction with blood glucose meters based on six factors (in order of importance): performance (26%); ease of use (24%); design (20%); features (19%); cost of test strips (6%); and training (5%). Satisfaction is calculated on a 1,000-point scale. Overall satisfaction with blood glucose meters has increased to 826 this year, up […]
When it comes to diabetes, the correct response to the above cliché is, “No kidding.” There’s no shortage of apps these days claiming to make life easier for PWDs (people with diabetes). Add two more to that ever-growing list.
News came early in the year about Sanofi’s new basal insulin called Toujeo, which is a higher concentration than the long-established Lantus.
On Wednesday morning, the California pump company announced that the FDA had approved its first combo device on Sept. 8 — about 14 months after Tandem Diabetes submitted the system for review.
In amazingly fast timing, the FDA has approved the next-generation Dexcom G5 continuous glucose monitor (CGM) system that will communicate directly with a mobile device, eliminating the need for a separate receiver!
Humalog® 200 units/mL KwikPen® (insulin lispro 200 units/mL; U-200), the first and only concentrated mealtime insulin analog in the U.S., is now available in pharmacies. Humalog U-200 KwikPen is a prefilled pen containing a concentrated formulation of Lilly’s rapid-acting insulin Humalog®
People who use insulin pump therapy to manage type 1 diabetes have a nearly 50 percent lower risk of dying from heart disease than people who take insulin through daily injections, according to a new study published in The British Medical Journal.
“As a concept, it doesn’t get a whole lot better than this,” says Dr. John Buse, co-senior author of the results of a study on the patch published in the Proceedings of the National Academy of Sciences and the director of the UNC Diabetes Care Center. “As a physician, I admit, I was stunned by […]
Sugary drinks are often blamed for the rise of type 2 diabetes and obesity, but few studies have examined the relationship between sweetened beverage consumption and people who are already physically fit.
According to a Fierce Medical Devices article, Medtronic released a customer notification letter on June 19th informing device users that there were instances when the bolus screen wouldn’t refresh properly, so the device might continue to show a bolus amount that was no longer accurate or appropriate.
It is important for people with diabetes– even patients who use an insulin pump – to properly prepare themselves before they engage in any type of physical activity.
The new technology, developed by a team at the University of Leeds in the United Kingdom, incorporates low-powered lasers in a small device that enables continuous blood sugar monitoring. Without the need for an implant, the device may be an ideal type of technology to develop into a wearable system.
The diabetes industry comes out en force and it was exciting to see many newsworthy announcements at a conference with so much direct access to people in the D-Community. Here’s what we captured our attention the most, from both the exhibit hall floor and the presentation sessions.
Checked out the new Apple Watch yet? One of the most exciting aspects for people with diabetes is the Dexcom G4 Share2 app you can use on the watch to view and share your glucose data results.
Locemia Solutions is developing a nasal glucagon delivery system that doesn’t require any mixing or needle jabs. The goal is to expand the field of people who might be able to help in a crisis, says Locemia CEO Claude Piché.
Researchers may have developed a patch that mimics the action of the pancreas; it senses increased levels of blood glucose and consequently releases the amount of insulin necessary to bring blood glucose levels within normal range. The patch has only been tested in mice with chemically induced type 1 diabetes.